Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺.
10.7534/j.issn.1009-2137.2014.05.011
- Author:
Yu JING
1
;
Cheng-Ying ZHU
1
;
Qi ZHANG
2
;
Jian-Hua NIU
3
;
Hua YANG
1
;
Shi-Yan LIU
4
;
Hai-Yan ZHU
1
;
Li YU
5
Author Information
1. Department of Hematology , Chinese PLA General Hospital, Beijing 1000853, China.
2. Department of Hematology, People's Hospital of Gaochun County, Nanjing 211300, Jiangsu Province, China.
3. Department of Hematology and Oncology, The Forth People's Hospital of Jinan, Jinan 250031, Shandong Province, China.
4. 4Department of Oncology, Traditional Chinese Medical Hospital of Taian, Taian 271000, Shandong Province, China.
5. Department of Hematology , Chinese PLA General Hospital, Beijing 1000853, China. E-mail: chunhuiliyu@ yahoo.com.
- Publication Type:Journal Article
- MeSH:
Aclarubicin;
administration & dosage;
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
therapeutic use;
Azacitidine;
administration & dosage;
analogs & derivatives;
Core Binding Factor Alpha 2 Subunit;
metabolism;
Cytarabine;
administration & dosage;
Granulocyte Colony-Stimulating Factor;
administration & dosage;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
metabolism;
Oncogene Proteins, Fusion;
metabolism;
RUNX1 Translocation Partner 1 Protein;
Recurrence;
Retrospective Studies;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(5):1245-1250
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the clinical characteristics of relapsed-refractory acute myeloid leukemia (AML) with AML1-ETO⁺, and its therapeutic efficacy and side effects when decitabine combined with modified CAG regimen was used. Clinical data of 5 cases of AML with AML1-ETO⁺ from January 2013 to Agust 2013 were analyzed retrospectively. The analyzed data included age, sex, initial symptoms, peripheral blood and bone marrow characteristics. Meanwhile, the therapeutic effecacy and side effects of decitabine combined with modified CAG regimen were evaluated. The 5 patients were with median age of 35 (17-43) years. Among these 5 patients, 2 patients were relapsed and other 3 patients were relapsed-refractory patients, their median white blood cell count was 12.55 (7.8-66.55) × 10⁹/L, median platelets count was 44 (20-72) × 10⁹/L, median hemoglobin level was 110 (77-128) g/L, median lactate dehydrogenase level was 312.9 U/L (123.6-877.8) at the initial diagnosis. The results showed that after decitabine combined with modified CAG regimen was administered, 4 patients achieved complete remission, 1 patient did not achieve remission, the overall remission rate was 80% (4/5). The main side effects of this regimen was myelosuppression, these were no new lung infection and other serious complications, one case without complete remission treated with FLAG once again died of heart failure when being mobilized for transplantation. It is concluded that according to preliminary results of decitabine combined with modified CAG regimen for relapsed and refractory AML patients with AML1-ETO⁺ displays higher remission rate and lower side effects, which worthy to further explore for clinal application.
